Pulmonx’s Q3 2026 Earnings: Revenue Grows, Loss Narrowing, and China Re-entry Looms as a Wildcard

Analyst read in the style of Matt Levine, with a focus on earnings, guidance, and strategic implications

Overview: the quarter in one line (and a half)

Pulmonx Corp (Nasdaq: LUNG) disclosed its third-quarter 2026 results, posting a net loss of $8.4 million, or $0.19 per share, versus a $14.0 million loss (or $0.34 per share) in the year-ago quarter. Revenue reached $22.8 million, up 6% year over year on both GAAP and constant currency bases. U.S. revenue was $14.9 million (up 7%), international revenue $7.9 million (up 5%), and excluding China, international revenue rose 9% on both GAAP and constant currency. The company notes a 76% gross margin for the quarter and highlights ongoing cost realignment that reduced net loss and Adjusted EBITDA loss versus the prior year.

The report underscores a transition story: a meaningful topline move in the quarter, improved operating leverage, and an explicit optionality around China as commercial activity restarts after a distributor pause and regulatory re-registration. The press release also flags non-cash stock-based compensation of about $14 million as part of the full-year cost structure.

Guidance and near-term financial shape

For the full year 2026, Pulmonx reiterates a revenue forecast in the $90–$92 million range and projects a gross margin of approximately 77%. Full-year operating expenses are expected to run between $108 million and $109 million, inclusive of roughly $14 million of non-cash stock-based compensation. Cash and cash equivalents totaled $52.7 million as of September 30, 2026. The company also projects that cash, cash equivalents, and marketable securities will decrease by about $22 million in 2026, assuming no additional draws on its credit facility.

Key operational highlights

Revenue mix and growth: Q3 2026 total revenue of $22.8 million represents a modest growth step, with U.S. revenue at $14.9 million and international revenue at $7.9 million. Excluding China, international revenue grew 9% year over year, signaling some geography-specific momentum despite regional headwinds.
Margins and expense discipline: Gross margin stood at 76% for the quarter. Operating expenses declined year over year (Q3 2026 vs Q3 2025: $24.9 million vs $30.4 million), reflecting cost realignment that produced a meaningful reduction in the loss metrics—Adjusted EBITDA loss improved by 57% versus the prior year.
Net income metrics: Net loss narrowed to $8.4 million, or $0.19 per share, from a $14.0 million loss or $0.34 per share a year earlier—an indicator that operating leverage is starting to bite, even if profits remain elusive on GAAP figures.
China exposure and timing: The company notes the absence of sales to its distributor in China as it restarts commercial activity following the renewal of its Chinese registration certificate, implying a potential revenue accelerator if the restart proceeds smoothly.
Non-cash considerations: About $14 million of stock-based compensation is included in the full-year guidance, highlighting a common medtech financing quirk: real operating leverage coexists with routine non-cash expenses that cushion or distort cash-based metrics.

Takeaways for Pulmonx and sector peers

The press release reads like a company that is serious about turning a cash-burner into a controlled burn. Revenue is headed in the right direction, but the business remains unprofitable on a GAAP basis. The margin expansion to 77% gross for the full year and the ongoing cost realignment are the levers for turning a narrative of “invest for growth” into one of “operating leverage proves out.” If the China restart gains traction, the path to profitability could become less hypothetical, but the timing remains uncertain—the regulatory cadence in China still matters to both Pulmonx and its peers exporting into the region.

For sector peers, the report reinforces a familiar script in medtech: incremental top-line improvements can be hollow without commensurate control of SG&A and R&D outlays, especially when a company carries non-cash stock-based compensation as part of its total comp. Investors will also watch whether the company can translate lower net losses and a steadier cash position into free cash flow generation or at least a more favorable net income trajectory over the next several quarters.

In markets where interventional pulmonology and minimally invasive devices are still undergoing adoption, the near-term stock trajectory often hinges on how quickly distributors revive in China and how effectively the company can sustain U.S. growth while expanding international contribution. The Q3 numbers give a cautious but plausible roadmap: keep revenue growing, keep costs disciplined, and do not overlook the importance of liquidity in a capital-light business model that still burns cash at a meaningful rate.

Earnings metrics and context

On an earnings-per-share basis, Pulmonx reported a loss of $0.19 in Q3 2026, improving from a $0.34 per-share loss in the year-ago quarter. The release presents GAAP results alongside Adjusted EBITDA, but does not publish a formal EPS consensus or a disclosed earnings surprise figure within the document. In practice, investors will infer surprises by comparing these results to street expectations once analysts publish updated models, making “EPS consensus” a live data point moving forward.

What’s next: the conference call and the runway ahead

Pulmonx scheduled a conference call and webcast for late October 2026 to discuss the third-quarter results. The cadence of guidance versus execution—especially around China re-entry, international momentum, and the sustainability of the gross margin—will likely set the tone for how the stock trades into year-end and how the company’s 2026 revenue forecast and expense plan are valued by investors and peers alike.